Xeris Biopharma (NASDAQ:XERS) Stock: Insider Steven Pieper Sells 5,000 Shares

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) insider Steven Pieper sold 5,000 shares of Xeris Biopharma stock in a transaction on Monday, November 2nd. The stock was sold at an average price of $10.23, for a total transaction of $51,150.00. Following the transaction, the insider directly owned 1,346,053 shares of the company’s stock, valued at $13,770,122.19. This represents a 0.37% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Steven Pieper also recently made the following trade(s):

• On Thursday, October 1st, Steven Pieper sold 5,000 shares of Xeris Biopharma stock. The shares were sold at an average price of $9.41, for a total transaction of $47,050.00.
• On Tuesday, September 1st, Steven Pieper sold 5,000 shares of Xeris Biopharma stock. The shares were sold at an average price of $8.50, for a total transaction of $42,500.00.
• On Wednesday, August 12th, Steven Pieper sold 5,000 shares of Xeris Biopharma stock. The shares were sold at an average price of $8.50, for a total transaction of $42,500.00.

Xeris Biopharma Stock Performance

Shares of Xeris Biopharma stock opened at $13.08 on Friday. The company has a current ratio of 1.45, a quick ratio of 1.02 and a debt-to-equity ratio of 17.00. The business has a 50-day moving average price of $9.49 and a two-hundred day moving average price of $7.58. Xeris Biopharma Holdings, Inc. has a 1-year low of $5.25 and a 1-year high of $13.74. The company has a market cap of $2.38 billion, a P/E ratio of -118.91 and a beta of 0.61.

Xeris Biopharma (NASDAQ:XERS) last announced its quarterly earnings data on Thursday, November 5th. The company reported $0.06 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.03 by $0.03. Xeris Biopharma had a positive return on equity of 338.21% and a negative net margin of 5.12%. The company had revenue of $107.23 million for the quarter, compared to the consensus estimate of $101.68 million. As a group, analysts anticipate that Xeris Biopharma Holdings, Inc. will post 0.07 EPS for the current year.

Hedge Funds Weigh In On Xeris Biopharma

Several institutional investors have recently made changes to their positions in XERS. BlackRock Inc. acquired a new stake in Xeris Biopharma in the 2nd quarter valued at $115,042,000. Wellington Management Group LLP increased its stake in Xeris Biopharma by 8.9% during the 2nd quarter. Wellington Management Group LLP now owns 2,365,103 shares of the company’s stock valued at $18,732,000 after purchasing an additional 193,749 shares in the last quarter. Legal & General Group Plc acquired a new position in Xeris Biopharma during the second quarter worth $15,941,000. Parkman Healthcare Partners LLC acquired a new position in Xeris Biopharma during the second quarter worth $14,316,000. Finally, Algert Global LLC raised its holdings in Xeris Biopharma by 50.6% during the second quarter. Algert Global LLC now owns 1,742,942 shares of the company’s stock worth $13,804,000 after buying an additional 585,984 shares during the last quarter. Institutional investors and hedge funds own 42.75% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have issued reports on XERS shares. Leerink Partners boosted their price target on Xeris Biopharma from $12.00 to $16.00 and gave the company an “outperform” rating in a research note on Thursday, September 10th. Weiss Ratings downgraded shares of Xeris Biopharma from a “hold (c-)” rating to a “sell (d-)” rating in a research report on Tuesday, August 11th. Barclays raised their price objective on shares of Xeris Biopharma from $12.00 to $14.00 and gave the stock an “overweight” rating in a research report on Tuesday, October 6th. Finally, Wall Street Zen upgraded shares of Xeris Biopharma from a “hold” rating to a “buy” rating in a research note on Saturday, September 19th. Four analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Xeris Biopharma currently has a consensus rating of “Moderate Buy” and an average price target of $13.20.

Key Headlines Impacting Xeris Biopharma

Here are the key news stories impacting Xeris Biopharma this week:

• Positive Sentiment: Xeris reported third-quarter earnings of $0.06 per share, beating the $0.03 consensus estimate, while revenue of $107.23 million topped expectations of $101.68 million. The better-than-expected results were a key near-term catalyst. Xeris Biopharma Shares Jump After Q3 Results Top Estimates
• Positive Sentiment: CEO John Shannon reportedly said Recorlev could approach $1 billion in annual sales three to four years earlier than previously expected, strengthening the company’s long-term growth story. Xeris CEO Sees Recorlev Nearing $1B in Annual Sales
• Neutral Sentiment: Several executives reported selling shares at $10.23 under pre-arranged Rule 10b5-1 plans. The reported sales were relatively small compared with their remaining holdings, which tempers the significance of the transactions. Xeris Insider Sale

Xeris Biopharma Company Profile

Xeris Biopharma, Inc is a specialty pharmaceutical company focused on developing and commercializing therapies for patients with endocrinology, gastroenterology and other serious or chronic conditions. The company uses proprietary formulation and delivery technologies designed to make complex therapies more stable, convenient and suitable for self-administration.

Xeris’ commercial portfolio includes Gvoke, a ready-to-use glucagon injection for the treatment of severe hypoglycemia in adults and children with diabetes; Recorlev (levoketoconazole), an oral therapy for endogenous hypercortisolemia associated with endogenous Cushing’s syndrome; and Keveyis (dichlorphenamide), a treatment for primary periodic paralysis.